Gilead Sciences (GILD)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$151.00-0.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
Research Workspace
Put GILD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Total revenue near $30.2 billion: FY26 revenue guidance $30.15B vs $30.2B target; Q2 revenue $7.8B (+10.0% YoY).
View ThesisRevenue is growing steadily — about 6% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 20%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskGilead Sciences' growth in HIV and oncology has to keep compounding to justify the price. Revenue grew 10% year over year, and the last quarter beat expectations. It trades at 6.2× price-to-sales versus an 11.4× peer median, indicating the price reflects less growth than forecast. A specific risk is the potential credibility hit if Gilead cuts guidance after recently raising it. Peer multiples imply a price about 30% above where it trades. Our read remains provisional.
Trailing returns as of 2026-09-04. GILD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering GILD (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for GILD in the last 4 months.
Continue this research
Compare GILD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GILD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put GILD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase product sales excluding Veklury
FDA approval boosts product sales growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $151.00
The last 12 months of price, then the range of analyst 12-month targets from today’s $151.00.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Advance HIV prevention with twice-yearly lenacapavir
FDA approval supports HIV prevention strategy with lenacapavir.
Advances: Advance HIV prevention with twice-yearly lenacapavir
FDA approval supports HIV prevention objective.
Advances: Complete acquisition of Arcellx and integrate oncology assets
EU approval supports oncology asset integration and sales growth.
Dependence on one franchise raises growth concerns.
Oncology strategy shift could enhance growth prospects.
Court ruling positively impacts Gilead's legal standing.
Potential pipeline catalyst could enhance growth.
